Summary:
double-blinded randomized study to assess the efficacy and safety of NYX-2925 in subjects with Fibromyalgia
Qualified Participants Must:
• Between 18-75 yrs of age
•
Fibromyalgia diagnosis greater than 1yr
• no history of bipolar
• no history of schizophrenia
• no autoimmune disease
• marijuana use allowed
Qualified Participants May Receive:
compensation for time and travel.